Archive for November 2019

Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure

Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.

Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.

Transcript

Given the benefits that DAPA-HF revealed in preventing the worsening of heart failure in patients without diabetes, what is the potential role of dapagliflozin in primary prevention?

Dapagliflozin has 2 key roles when it comes to thinking about heart failure. The first is we have very strong evidence that dapag liflozin, and the whole SGLT2 inhibitor family, reduce the risk of incident heart failure. So, if you've got type 2 diabetes, 1 of the major risks you face is developing heart failure, and dapagliflozin, like other SGLT2 inhibitors, unequivocally reduces that risk substantially. What's new is that we now know that dapagliflozin is also a treatment for established heart failure. So, moving from prevention to treatment, we can treat patients with heart failure both with and without type 2 diabetes.

Leave a comment

Cancer drug neratinib offers hope for type 1 diabetes treatment

A drug used to treat breast cancer, neratinib, has the potential to halt the immune system from destroying beta cells in type 1 diabetes, according to German researchers.

Neratinib was able to guard the beta cells, which produce insulin in the pancreas, from attack. The JDRF-funded study showed that the treatment enabled the beta cells to continue to produce insulin.

When someone with type 1 diabetes is diagnosed with the condition, typically they have 10 to 20% of beta cells remaining. The researchers hope that early intervention could help to preserve the number of beta cells following diagnosis.

If the drug is effective at preserving the number of beta cells, it could make it easier for people with type 1 diabetes to control their blood glucose levels, and reduce the amount of insulin they may need to take by injection or insulin pump.

The researchers from the University of Bremen explored whether the drug could stop the process behind the immune system attack in type 1 diabetes. In experiments, they tested whether neratinib on cells, similar to beta cells grown in a laboratory. They then explored whether neratinib could protect human beta cells. Additionally, they tested the drug in mice which had a condition similar to type 1 diabetes.

According to the results, neratinib halted the destruction of beta cells in lab-grown beta cells and human beta cells. When neratinib was not used, the same sets of cells died.

In the mouse experiments, those given neratinib were able to produce more insulin compared to those not treated with the drug. Also, the mice treated with neratinib had significantly lower blood glucose levels throughout the study, which lasted 35 days.

Commenting on the findings of the study, a JDRF spokesman said: "Although still in its early stages, this research reveals an exciting possible use for the cancer therapy neratinib in preventing beta cell death and preserving insulin production in type 1.

"In the future, this therapy could allow people with type 1 to continue to produce some of their own insulin, making them less reliant on insulin injections or pumps while having better blood glucose management. Coupled with a way to regenerate the beta cells already lost, therapies – such as neratinib – which prevent beta cell death may even lead to a functional cure for type 1."

The study was published in the journal Nature Communications.

Leave a comment

Diabetes Therapies Market Research and Clinical Analysis 2019

Nov 28, 2019 (Market Insight Reports via COMTEX) -- The report presents an in-depth assessment of the Diabetes TherapiesMarket including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Diabetes Therapies investments from 2019 till 2022.

Request a Sample copy of this report at:

https://www.marketinsightsreports.com/reports/03261159757/diabetes-therapies-global-market-opportunities-and-strategies-to-2023-including-injectables-oral-covering-novo-nordisk-a-s-eli-lilly-and-company-sanofi-s-a-merck-company-c-h-boehringer-sohn-ag-ko-kg/inquiry?Mode=49

Summary:

The diabetic therapies market consists primarily of manufacturers sales of drugs for treating diabetes. The drugs most commonly used are alpha-glucosidase inhibitors, biguanides/metformin, sulfonylureas, meglitinides and thiazolidinediones. Innovative techniques relating to diabetes therapies research and development include gene editing, and identification of microbial strains for treatment of diabetes. These advances have created new treatments for diabetes.

The diabetic therapies market reached a value of nearly $50.7 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 6.4% to nearly $69.3 billion by 2023. Anti-diabetic drugs in the form of oral and injectable drugs are used for treatment of type 1, type 2 and gestational diabetes. Factors such as rising disposable income and increasing spending on healthcare in emerging markets, increasing grants from government agencies for diabetic therapies drugs research and development and rising awareness of this disease globally are contributing to the growth of the market. Potential threats include pressure from regulators on diabetic drugs manufacturers to offer diabetic drugs at affordable prices, drug patent expiry, high drug discovery and development costs and rising trade protectionism.

North America is the largest region in the diabetic therapies market, accounting for 39.2% of the global market in 2018. It was followed by Asia Pacific and Western Europe. Going forward, the fastest growth in the diabetic therapies market is predicted for Asia Pacific, where it is expected at grow at a CAGR of 12.3%, followed by Africa at a CAGR of 6.9%. The largest country in terms of value in the diabetic therapies market is the USA. China and India are forecast to have the fastest growth at CAGRs of 16.7% and 13.3% respectively.

(special offer:Get flat 20% discount on this report)

Avail Discount on this report at:

https://www.marketinsightsreports.com/reports/03261159757/diabetes-therapies-global-market-opportunities-and-strategies-to-2023-including-injectables-oral-covering-novo-nordisk-a-s-eli-lilly-and-company-sanofi-s-a-merck-company-c-h-boehringer-sohn-ag-ko-kg/discount?Mode=49

Scope of The Report:

Companies Mentioned: Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Company, C.H. Boehringer Sohn AG & Ko. KG

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, Diabetes Therapies indicators comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Browse full report along with TOC and List of Figures at:

https://www.marketinsightsreports.com/reports/03261159757/diabetes-therapies-global-market-opportunities-and-strategies-to-2023-including-injectables-oral-covering-novo-nordisk-a-s-eli-lilly-and-company-sanofi-s-a-merck-company-c-h-boehringer-sohn-ag-ko-kg?Mode=49

Description:

Where is the largest and fastest growing market for the Diabetes Therapies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Diabetes Therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider transportation manufacturing market, and compares it with other markets.

Reasons for Buying this Report:

  • Outperform competitors using accurate up to date demand-side dynamics information.Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings.
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Gain a global perspective on the development of the market.
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
  • We also offer customization on reports based on specific client requirement:

    1-Free country level analysis for any 5 countries of your choice.

    2-Free Competitive analysis of any 5 key market players.

    3-Free 40 analyst hours to cover any other data points.

    About Us:

    MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

    Contact Us:

    Irfan Tamboli (Head of Sales) - Market Insights Reports

    Phone: + 1704 266 3234 | +91-750-707-8687

    sales@marketinsightsreports.com |irfan@marketinsightsreports.com

    COMTEX_358153433/2599/2019-11-28T23:23:05

    Leave a comment

    Gut microbes may predict whether exercising will prevent diabetes

    woman sitting downHow much we benefit from exercise may be down to our gut microbiome

    AzmanJaka/Getty Images

    Your gut microbes may determine how you respond to exercise. That is according to research showing how people with certain microbiomes have better metabolic outcomes after exercise. The discovery opens the door to diabetes treatments that target the microbes in our gut.

    Type 2 diabetes is a growing problem internationally. While there is no cure, it can be prevented by early lifestyle interventions, says Aimin Xu at the University of Hong Kong.

    "Exercise is the most cost-effective strategy for diabetes prevention," he says. "However, some people do not respond favourably to exercise."

    Advertisement

    To understand why, Xu and his colleagues studied how exercise affected the microbiome and metabolism of 39 men with prediabetes, where blood sugar levels are higher than normal, but not high enough to qualify for a diagnosis of diabetes.

    The participants, who had never taken medication for the condition, were randomly assigned either to a sedentary control group, or to a group that undertook a three-month, high-intensity, supervised exercise training course. They were told to maintain their usual diet.

    While all participants in the exercise group had similar levels of weight and fat-mass reduction, only 70 per cent had significant improvements in glucose metabolism and insulin sensitivity, Xu found.

    An analysis of their gut microbes revealed that the people who saw improvements in glucose metabolism and insulin sensitivity had significantly different microbiomes that were able to generate more molecules called short-chain fatty acids and break down more branched-chain amino acids. the microbiomes of non-responders were more likely to produce compounds that are harmful to metabolism.

    Next, the researchers asked the study participants to provide faecal samples, and transplanted the microbes they contained into obese mice. Rodents receiving microbes from people who responded well to exercise went on to develop better insulin resistance and glucose regulation. The rodents receiving microbes from people who hadn't responded to exercise didn't see any boost to these processes.

    "[Our study] identifies maladaptation of gut microbiota as a "culprit" for those individuals who do not respond to exercise intervention," says Xu. "This is one of the first interventional randomised control trial studies providing clear evidence of the role of gut microbiota on metabolic health."

    The findings raise the possibility that targeting gut microbiota can maximise the benefit of exercise and could help doctors personalise treatments.

    The study only included men. Gut microbiomes can differ depending on sex, so the team plans to undertake similar research into women and older people in the future.

    Journal reference: Cell Metabolism, DOI: 10.1016/j.cmet.2019.11.001

    More on these topics:

    Leave a comment

    Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japan

    POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, announced today positive topline Phase 3 results from the 36-week, open-label extension period of the TIMES 3 trial, which evaluated Imeglimin in combination with insulin for the treatment of type 2 diabetes. Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase 3 program in Japan includes three pivotal trials to evaluate Imeglimin's efficacy and safety in over 1,100 patients.

    "I am very excited to contribute to the development of a new and innovative potential treatment option for Japanese patients with type 2 diabetes," said Professor Hirotaka Watada, MD, PhD, Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan. "Given the efficacy of Imeglimin observed in this insulin-treated population combined with the favorable safety and tolerability profile, I believe it has the potential to provide a new treatment option to help manage glycemic control in these patients."

    As previously announced, the 16-week, double-blind placebo-controlled randomized portion of the TIMES 3 trial was observed to demonstrate efficacy and achieved statistical significance (p<0.0001) for its primary endpoint, defined as a change of glycated hemoglobin A1c (HbA1c) from baseline versus placebo at week 16, with a mean HbA1c placebo-corrected change from baseline of -0.60%.

    In the open-label extension period, which was not placebo-controlled, 208 Japanese patients who completed the first 16 weeks of the study were administered 1,000 mg Imeglimin orally twice-daily as well as insulin therapy for the next 36 weeks. The HbA1c decrease observed at the end of the open-label extension period was:

  • -0.64% versus baseline in patients receiving Imeglimin and insulin for 52 weeks (Imeglimin and insulin for 16 weeks followed by Imeglimin and insulin for 36 weeks).
  • -0.54% versus baseline in patients receiving Imeglimin and insulin for the last 36 weeks only (placebo and insulin for 16 weeks followed by Imeglimin and insulin for 36 weeks).
  • The results of this study were observed to demonstrate sustained efficacy of Imeglimin as an add-on therapy to insulin.
  • Overall, the safety and tolerability profile of Imeglimin was observed to be favorable for the entire portion of the 52-week trial. In the first 16-week double-blind placebo-controlled treatment period, the incidence of treatment emergent adverse events was similar to the placebo group. In the 36-week extension period, the safety and tolerability profile was consistent with the first part of the trial. There were no episodes of severe hypoglycemia events and the majority of the hypoglycemia events reported were mild.

    "Despite efforts to manage type 2 diabetes with diet and oral agents, many patients transition to insulin therapy as a natural part of the disease progression. We are very pleased with the sustained efficacy observed for Imeglimin over a one-year period in combination with insulin," said Thomas Kuhn, CEO of Poxel. "These data demonstrate efficacy with a favorable safety and tolerability profile in a different patient population than the TIMES 1 monotherapy trial and we are looking forward to the TIMES 2 results evaluating Imeglimin in combination with marketed therapies available in Japan. We are continuing to work very closely with our partner, Sumitomo Dainippon Pharma, in preparing for the Japanese New Drug Application and the TIMES 3 results bring us one step closer to achieving that goal."

    Poxel anticipates presenting full data results from the Phase 3 TIMES 3 trial at an upcoming scientific meeting.

    About the Phase 3 TIMES Program TIMES (Trials of Imeglimin for Efficacy and Safety), the Phase 3 program for Imeglimin for the treatment of type 2 diabetes in Japan, consists of three pivotal trials involving over 1,100 patients. The TIMES program is a joint development effort between Poxel and Sumitomo Dainippon Pharma Co., Ltd. The companies entered into a strategic partnership in October 2017 for the development and commercialization of Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast and East Asian countries1. The TIMES program includes the following three trials that will be performed using the dose of 1,000 mg twice daily:

    TIMES 1: A Phase 3, 24-week, double-blind, placebo-controlled, randomized, monotherapy trial to assess the efficacy, safety and tolerability of Imeglimin in Japanese patients with type 2 diabetes, using the change in HbA1c as the primary endpoint. Secondary endpoints of the trial include fasting plasma glucose, other standard glycemic and non-glycemic parameters. The TIMES 1 trial met its primary and secondary endpoints and the topline results were reported on April 9, 2019.

    TIMES 2: A Phase 3, 52-week, open-label, parallel-group trial to assess the long-term safety and efficacy of Imeglimin in Japanese patients with type 2 diabetes. In this trial, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor, biguanide, sulphonylurea, glinide, alpha-glucosidase inhibitor, thiazolidine and GLP1 receptor agonist. The TIMES 2 topline results are expected around the end of 2019.

    TIMES 3: A Phase 3, 16-week, double-blind, placebo-controlled, randomized trial with a 36-week open-label extension period to evaluate the efficacy and safety of Imeglimin in combination with insulin in Japanese patients with type 2 diabetes and inadequate glycemic control on insulin therapy. The TIMES 3 16-week portion of the trial met its primary endpoint with a favorable safety and tolerability profile observed and the topline results were reported on June 25, 2019.

    About Imeglimin Imeglimin is the first clinical candidate in a new chemical class of oral agents called Glimins by the World Health Organization. Imeglimin has a unique mechanism of action (MOA) that targets mitochondrial bioenergetics. Imeglimin acts on all three key organs which play an important role in the treatment of type 2 diabetes: the pancreas, muscles, and the liver, and it has demonstrated glucose lowering benefits by increasing insulin secretion in response to glucose, improving insulin sensitivity and suppressing gluconeogenesis. This MOA has the potential to prevent endothelial and diastolic dysfunction, which can provide protective effects on micro- and macro-vascular defects induced by diabetes. It also has the potential for protective effect on beta-cell survival and function. This unique MOA offers the potential opportunity for Imeglimin to be a candidate for the treatment of type 2 diabetes in almost all stages of the current anti-diabetic treatment paradigm, in cluding monotherapy or as an add-on to other glucose lowering therapies.

    About Poxel SA Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel's first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin's development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com.

    All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

    1 including Indonesia, Vietnam, Thailand, Malaysia, The Philippines, Singapore, Republic of the Union of Myanmar, Kingdom of Cambodia and Lao People's Democratic Republic.

    Leave a comment

    Much-needed cost relief for Medicare patients with diabetes

    The most recent study from the American Diabetes Association (ADA) reports that over 30 million people currently have diabetes in the United States and a staggering 84 million people are pre-diabetic. The study also found that, on average, healthcare costs for those with diabetes are 2.3 times higher than those without diabetes, and one in every seven dollars spent on healthcare in our country goes toward treating diabetes and related complications.

    Photo provided by Essence Healthcare

    Managing diabetes for older adults can be particularly challenging, especially when it comes to the cost of treatment, supplies and medication. Many older adults are on a fixed income and thus shouldering the out-of-pocket costs associated with proper treatment of diabetes can be difficult. As medical costs mount, some patients elect to forgo their treatment, which puts them at risk for further complications.

    Fortunately, there is good news for diabetic patients on Medicare. The Centers for Medicare and Medicaid Services (CMS) â€" the federal agency that oversees and administers the Medicare program â€" has made recent changes that allow health plans more flexibility to help patients with the cost of their diabetes and to better manage their condition.

    St. Louis’ local Medicare plan, Essence Healthcare is one of the first in the country to take advantage of this regulation change and tackle the problem head-on. Essence Healthcare has been providing Medicare coverage to people throughout the St. Louis area for over 15 years and currently serves over 55,000 people throughout the community. Just recently, Essence Healthcare announced a new package of benefits that provides significant cost relief for those with diabetes.

    Photo provided by Essence Healthcare

    This package of benefits is included in the company’s $0 premium Medicare Advantage plan and offers $0 copays for insulin, testing supplies, primary care visits, diabetic eye exams and diabetic counseling. In addition, members with diabetes in the Essence Advantage (HMO) and Essence Advantage Plus (HMO) plans receive an additional $50 allowance for approved over-the-counter items each quarter.

    “We have seen the rise of diabetes in our community and were concerned about the subsequent strain it puts on older adults on fixed incomes,” said Richard Jones, CEO of Essence Healthcare. “We decided we need to tackle it head-on by removing cost barriers to proper treatment and ensuring our members get access to great primary care physicians to help them manage and treat their diabetes. We think it can really make a difference in patients’ lives.”

    People with diabetes who may benefit from this plan can join during the Medicare Annual Enrollment Period which runs from October 15 through December 7. For information about the Essence Healthcare plan, visit essencehealthcare.com.

    This content was produced by Brand Ave. Studios in collaboration with Essence Healthcare. The news and editorial departments of the St. Louis Post-Dispatch had no role in its creation or display. For more information about Brand Ave. Studios, contact tgriffin@stltoday.com. Y0027_20-262_M Essence Healthcare is an HMO plan with a Medicare contract. Enrollment in Essence Healthcare depends on contract renewal. Essence Healthcare complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

    Leave a comment

    What Triggers Type 1 Diabetes?

    Share on Pinterest

    When my type 1 diabetes (T1D) was diagnosed in 1962, scientists couldn't explain the cause of the disease or what triggered it. Fifty-seven years later, I'm still waiting for researchers to tell me precisely why my pancreas stopped making insulin and my blood sugar shot up so high that I needed to be hospitalized.

    Still, while researchers continue to search for a full explanation of what causes T1D, they've solved more than a few diabetes-related mysteries. They've identified specific risk factors and come up with evidenced-based theories about what triggers this disease.

    Many of the scientific detectives trying to track down culprits for T1D are also trying to explain why it is surging: T1D is increasing at a rate of 5.3 percent globally every year, by one estimate. Read on to learn more about what we know — and don't know — about why.

    How does type 1 diabetes develop?

    If you or someone you love has T1D, you probably know the basic explanation for the disease: it occurs when the body's immune system destroys the insulin-producing cells (beta cells) in the pancreas. It can occur at any age, although it's much more common in kids.

    It's less well-known that T1D starts developing before symptoms appear. In fact, the national experts at JDRF, the American Diabetes Association, and the Endocrine Society now agree that there are three distinct stages of T1D development:

  • Stage 1: Biochemical signs of an attack on insulin-producing cells, called "autoantibodies," start showing up. But at this stage the patient feels no symptoms and the blood sugar remains normal.
  • Stage 2: The immune system has destroyed enough insulin-producing cells to cause abnormal blood sugar levels, but there are still no symptoms. Most people have no idea that they have diabetes at this stage.
  • Stage 3: Enough insulin-producing cells have been destroyed for symptoms to start showing up. They include increased thirst, frequent urination, extreme hunger, weight loss, fatigue, irritability, blurred vision, and a fruity smell on the breath from ketones (which the body produces when it burns fat to get energy).
  • Known risk factors for type 1 diabetes

    There are several risk factors that make it more likely that someone will develop T1D, including:

    Genes and family history

    Several specific genetic markers have been identified, and if you have one or more of them, you might develop T1D. Since genes are inherited, family history is an important predictor for T1D. If you have a relative with T1D, your risk of developing it is 1 in 20.

    But according to researchers, less than 10 percent of people with these genetic markers develop T1D. So it's clear that other factors besides genes put people at higher risk for developing the disease.

    Race/ethnicity

    Certain ethnic groups have a higher rate of T1D. In the United States, for example, whites are more likely to develop T1D than African Americans and Hispanic Americans.

    Geography

    Where you live influences your chances of developing T1D as well. In China, T1D rates are 10 to 20 times lower than in North America, Europe, and Australia. Finland has the highest incidence of T1D in the world.

    The American Diabetes Association acknowledges that "Type 1 diabetes develops more often in winter than summer and is more common in places with cold climates." And on the flip side, "people who live in southern climates — such as South America — are less likely to develop type 1." There is a related theory that because people in less sunny regions are more prone to T1D because they get less vitamin D — which comes directly from the sun.

    Other autoimmune conditions

    Autoimmune conditions often seem to come in pairs. So if someone has Graves' disease, multiple sclerosis, pernicious anemia, or other autoimmune conditions, they are more likely to develop T1D.

    Searching for triggers

    Clearly, some kind of trigger is needed for the immune system to attack insulin-producing cells in people who are genetically susceptible to T1D. Here are a few of the potential triggers that have been identified:

    Viral infections and type 1 diabetes

    There is a lot of anecdotal evidence that people are diagnosed with T1D after experiencing some kind of viral infection.

    "Scientists believe that certain viruses may target beta cells, and as the immune response ramps up to fight those viruses, it goes awry and attacks uninfected beta cells by mistake," according to JDRF.

    Animals and people with specific strains of infectious viruses, called "enteroviruses," are more likely to get diabetes. It's long been known that epidemics of mumps, rubella, and coxsackie viruses have been associated with increased frequency of type 1.

    Toxins and type 1 diabetes

    Other research indicates that toxins in the air, water, and food might trigger T1D in people who are genetically prone to it. Some studies reveal a higher incidence of the disease in people exposed to arsenic, while others have linked it to nitrates, ozone, sulfates, and other chemicals and pollutants.

    The "accelerator hypothesis" and "double diabetes"

    The notion of an overlap between type 1 and type 2 diabetes has been a topic of research since the 1990s. From this work comes the "accelerator hypothesis," which posits that obesity-associated insulin resistance can accelerate the onset and progression of T1D. The idea is that the beta cells are further stressed, which makes them more susceptible to autoimmune attack.

    Also, with the incidence of diabetes in obese young people on the rise — and growing difficulty distinguishing type 1 from type 2 in some patients — scientists have also coined the term "double diabetes" to refer to coexistence of autoimmunity and insulin resistance.

    Diet and type 1 diabetes: Is there a connection?

    Despite some public misconception, the onset of T1D has never been linked to consuming too many sweets or even overeating in general. But there are some specific foods that researchers suspect may play a role.

    In the 1980s, there was a lot of excitement among researchers about studies showing that kids who ate cow's milk-based foods at a very young age ran a higher risk of developing T1D. One long-term study tested the idea that weaning infants to a special kind of formula would reduce the risk. Alas, that didn't work!

    But the role of cow's milk is still being investigated. There is also some evidence linkingcereals,gluten (wheat protein), root vegetables, and omega-3 fatty acids to an elevated risk of T1D.

    Also, as noted above, some studies indicate that people who get more vitamin D from sunshine are less prone to T1D. Dan Hurley calls this theory "the sunshine hypothesis" in his very enlightening book, "Diabetes Rising."

    If that's true, would taking vitamin D supplements help prevent the disease? A review of relevant research in Lancet notes that "there is surprisingly little supporting evidence" for this idea.

    Other physical and psychological triggers

    Unfortunately, we've just scratched the surface here, as scientists are still investigating a whole array of other factors that might also influence the development of T1D:

  • frequent early childhood respiratory or gastrointestinal infections
  • Rapid growth and weight gain in children
  • low physical activity during puberty
  • trauma or serious life events, such as divorce or death in the family
  • stress (via increased cortisol concentrations)
  • Weakened immune systems?

    While trying for decades to identify the risk factors for T1D, scientists have also been struggling to understand its underlying causes and why its incidence is increasing, especially in developed countries.

    One idea that got tons of publicity in the 1990s is the "hygiene hypothesis," which proposes that people in the developed world are too clean for our own good. The idea is that advanced sanitation has weakened our immune systems, because they no longer have to fight off so many germs and infections. So instead, the theory proposes, the immune system goes haywire and attacks healthy cells in the body.

    There hasn't been conclusive evidence to support a direct connection between improved hygiene and T1D, but one current hypothesis is a closely related notion. It poses that as children, we need to be exposed to a broad range of little microbes to teach the immune system to distinguish between the body's friends and foes. If kids don't get enough contact with these harmless microorganisms that have been present throughout human evolution, their immune systems may not get properly trained. And one consequence could be T1D.

    There is also emerging evidence of a link between the so-called "microbiome" — the tiny organisms inside of the gut — and T1D. Scientist pose that people might need the right combinations of these little organisms for the immune system to function properly and not turn against insulin-producing cells.

    None of this is yet conclusive, so the quest to understand why T1Ds' immune systems are compromised continues.

    Can type 1 diabetes be avoided?

    Unfortunately, no one has come up with a unified theory that convincingly explains the possible interactions between genes, viruses, the environment, diet, microbes, and other potential contributors to T1D.

    Without nailing the causes, science hasn't been able to offer us convincing steps people can take to prevent T1D. Not yet, that is.

    Two long-term studies are underway to sort some of this out. The first is called TrialNet, a network of leading T1D research clinic sites around the world that is testing children who are a direct relative of someone with T1D — a parent, sibling, aunt, uncle, cousin, or grandparent — to learn about how this disease may be inherited.

    The second is called The Environmental Determinants of Diabetes in the Young (TEDDY) study, which is keeping track of children with genetic markers of T1D and trying to determine what prompts some of them to get the disease while others remain diabetes-free.

    Let's keep hoping that researchers will eventually unravel the mystery of what causes T1D. That might help them come closer to finding a way to prevent and even cure it.

    This article has been medically reviewed by Maria Basina, MD, on 11/19/2019.

    Leave a comment

    Sanofi's Positive Diabetes Study Offers A New Treatment Alternative For Patients

    To ensure this doesn't happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.

    If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

    Reference ID:

    Leave a comment

    Kadimastem Announces Successful Preclinical Results of Its Cell Therapy Treatment for Insulin-dependent Diabetes

    Study results demonstrate IsletRx cells ability to balance blood sugar levels and maintain normal levels over time

    Unique technology developed by the Company protects IsletRx cells from host immune system response, overcoming a major challenge faced by the Cell Therapy industry

    NESS ZIONA, Israel, Nov. 19, 2019 /PRNewswire/ -- Kadimastem Ltd. (KDST.TA), a clini cal stage cell therapy company, today announced successful results of its preclinical proof-of-concept study of IsletRx, an "off-the-shelf" cell product for the treatment of Insulin Dependent Diabetes. IsletRx is comprised of highly purified functional human pancreatic islet cells integrated with a microencapsulation technology developed by the Company.

    IsletRx is comprised of highly purified functional human pancreatic islet cells integrated with unique microencapsulation technology, protecting the cells from immune system response. Depicted in the graph are the prolonged normalized blood sugar levels in treated immunocompetent diabetic mice.

    More

    The Company reports that study objectives have been achieved, as study results show safe delivery of IsletRx and demonstrate efficacy manifested by prolonged normalized blood sugar levels in treated immunocompetent diabetic mice throughout the duration of the preclinical study (3 months). Furthermore, n o disease or treatment related complications were observed, and all treated animals remained healthy throughout study duration. In comparison, a control group of non-treated diabetic mice presented severe hyperglycemia, leading to the death of the non-treated mice within 40 days.

    The unique microencapsulation technology, integrated within the IsletRx, protected the islet cells from host immune system response, without the need for potentially toxic immunosuppressive drug treatment. 

    Based on these results, the Company continues to advance its IsletRx development program towards the clinical stage. The Company plans to engage in discussions with the U.S. Food and Drug Administration (FDA) during H1 2020. The Company estimates that additional pre-clinical studies will be required, with results expected during H1 2021. These results will suppor t further discussions with the FDA regarding an Investigational New Drug (IND) application later that year, in order to advance IsletRx to the clinical stage.

    Prof. Michel Revel, Founder and CSO of the Company, stated "Not only do these results demonstrate the high quality of our cells but also our ability to overcome major challenges faced by the cell therapy industry, the delivery method of cells and the need to protect them from the host immune system w ithout the requirement for immunosuppressive drugs. We are excited by this significant progress, as we further develop our ability to provide treatment to millions of Insulin-Dependent Diabetes patients."

    Rami Epstein, CEO of the Company, added: "The IsletRx product targets a multi-billion dollar market, which currently offers only repeated daily insulin injections. This achievement is an additional validation of our scientific and technological capabilities, positioning us in the forefront of the cell therapy industry." 

    About Insulin-Dependent Diabetes

    Diabetes is one of the 21st century's largest global health epidemics. It is a chronic disease characterized by high blood sugar levels and sugar intolerance due to insulin deficiency, impaired insulin effectiveness or both. Diabetes complications include cardiovascular diseases, kidney failure, and neuropathies, and increase the risk of serious vision disorders, such as cataracts and glaucoma. According to the International Diabetes Federation (IDF), in 2017 there were 424.9 Million people who suffered from diabetes and by 2045, the number is expected to increase to 628.6 Million. The American Diabetes Association (ADA) estimates the annual costs of diabetes patients in the US alone at $223.5 Billion. The global costs are estimated at $465 Billion and expected to reach $510 Billion by 2030.

    Story continues

    Two types of diabetes, type 1 and type 2, are different in their causes and clinical representation. All type 1 diabetes and 30% of type 2 diabetes patients depend on the administration of insulin for managing their glucose levels in the blood. According to Prescient & Strategic (P&a mp;S) Intelligence Private Limited market report (2018), the global human insulin market was valued at $42.9 Billion in 2017 and is projected to register a CAGR of 8.8% to reach $70.6 Billion in 2023.

    About IsletRx

    IsletRx is cellular product developed and manufactured by the Company based on its proprietary Technology Platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into clinical grade functional cells for the treatment of multiple diseases. IsletRx contains pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels. IsletRx is produced utilizing proprietary method of the Company, which includes a unique stage for functionally active cells using newly specific cell surface biomarkers. In addition, a unique microencapsulation technology, integrated within IsletRx, protects the islet cells from the host immune system, thus allowing prolonged therapeutic effect. IsletRx is intended for the treatment of Insulin Dependent Diabetes, aiming to free patients from continuous monitoring of blood sugar levels and repeated insulin injections.

    About Kadimastem

    Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic proprietary cell products based on its platform technology for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into clinical grade functional cells.  AstroRx®, the Company's lead program, is a clinical-grade astrocyte cell therapy for the treatment of ALS, currently undergoing a Phase 1/2a clinical trial. In addition, preclinical trials are ongoing with the Company's IsletRx pancreatic functional islet cells for the treatment of insulin dependent diabetes. Kadimastem was founded by Prof. Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Prof. Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug with annual sales of billions of dollars worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (KDST.TA).

    Forward Looking Statement

    This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular, bears risks. One should take into account that past performance does not necessarily indicate performance in the future.

    Company Contacts:

    Yossi Nizhar, CFO                                                   y.nizhar@kadimastem.com+972-73-797-1613                                                         

    Investor and Media:Meirav Gomeh-Bauermeirav@bauerg.com+972-54-476-4979

    Global Media & Collaborations:Dasy Mandel, Director of Business Developmentd.mandel@kadimastem.com+972-73-797-1601

     

    View original content to download multimedia:http://www.prnewswire.com/news-releases/kadimastem-announces-successful-preclinical-results-of-its-cell-therapy-treatment-for-insulin-dependent-diabetes-300960989.html

    Leave a comment

    Diabetes Research Institute and Biorep Technologies Commemorate 25-year Partnership Toward a Diabetes Cure

    MIAMI, Nov. 20, 2019 /PRNewswire/ -- The Diabetes Research Institute (DRI) has made significant progress toward a cure – thanks in large part to dedicated Miami father Ramon Poo , whose company Biorep Technologies, Inc., has manufactured critical research equipment envisioned by DRI scientists. During November's Diabetes Awareness Month, Biorep commemorates its 25th anniversary and a partnership with the DRI born out of a commitment to cure the disease.

    In the mid-70s, Poo's daughter, Cristina, was diagnosed with type 1 diabetes at just 3 years old. He and his wife, Tina, quickly got involved with the Diabetes Research Institute Foundation to help raise money to find a cure. But as an engineer and owner of Altira Inc., a Miami-based plastic bottle manufacturing company, he knew he could do more.

    An opportune meeting with a then-young scientist and inventor, Camillo Ricordi , M.D., who is now director of the Diabetes Research Institute and Cell Transplant Center at the University of Miami, was the start of this enduring r elationship and a new company, Biorep Technologies, created in 1994. Now, 25 years later, Poo [pronounced Pō] has worked side by side with DRI scientists to design and manufacture dozens of patented medical devices, which are distributed to leading pharmaceutical and medical institutions around the world.

    It all started with the Ricordi Chamber, the device invented by Dr. Ricordi that makes islet cell transplantation, a procedure that can restore insulin production in diabetes patients, possible.

    "We originally built the Ricordi Chamber from scratch. We tried to find companies interested in helping us but were unable to find anyone that was willing to produce it," explained Dr. Ricordi, who is acknowledged by his peers as one of the world's leading scientists in diabetes cure-focused research and cell transplantation. "It was thanks to Ramon Poo that we started producin g the first chambers with state-of-the-art technology."

    Demand for the device increased as the Ricordi Chamber became the standard piece of equipment used by doctors working in islet transplantation the world over. As needs grew, Poo decided to create a new business entity that would develop innovative products to help researchers defeat diabetes. According to Managing Director Felipe Echeverri , all Biorep's diabetes equipment initiates from the DRI.

    "We're not scientists; we're engineers. All the biology and science behind the ideas come from them," said Echeverri. "We get a lot of calls from different universities and research centers around the world, and we ship the technologies developed at the DRI to over 35 countries now."

    For Poo, it's all about getting good results that will help lead to a cure for his daughter and millions more. As he looks back on the countless hours and money he has donated to the cause: "We just said this is something we have to do, and we do it. We all have the dream of finding the cure."

    Get the whole story and video at DiabetesReseach.org/biorep

    About the Diabetes Research Institute and Foundation

    The mission of the Diabetes Research Institute Foundation is to provide the Diabetes Research Institute with the funding necessary to cure diabetes now. The Diabetes Research Institute at the University of Miami Miller School of Medicine leads the world in cure-focused research. As one of the largest and most comprehensive research centers dedicated to curing diabetes, the DRI is aggressively working to develop a biological cure by restoring natural insulin production and normalizing blood sugar levels without imposing other risks. Researchers have already shown that transplanted islet cells allow patients to live without the need for ins ulin therapy. Some study participants have maintained insulin independence for more than 10 years. The DRI is now building upon these promising outcomes through its BioHub strategy, a multidisciplinary, three-pronged approach for addressing the major challenges that stand in the way of a cure: eliminate the need for anti-rejection drugs, reset the immune system to block autoimmunity, and develop an unlimited supply of insulin-producing cells. For more information, please visit DiabetesResearch.org or call 800-321-3437.

    About Biorep Technologies, Inc.

    Story continues

    Biorep Technologies, Inc., was founded in 1994 as a privately owned family business with the mission to help the Diabetes Research Institute (DRI) with their research efforts to find the biological cure for type I diabetes. As a full-service development firm, Biorep has an exclusive focus on medical products and over 25 years of experience developing medical devices. Biorep is ISO 13485 certified and FDA registered. For more information, visit Biorep.com or call 305-330-4449.

     

    Diabetes Research Institute logo. (PRNewsFoto/Diabetes Research Institute Foundation) (PRNewsfoto/Diabetes Research Institute F...)

    More

    View original content to download multimedia:http://www.prnewswire.com/news-releases/diabetes-research-institute-and-biorep-technologies-commemorate-25-year-partnership-toward-a-diabetes-cure-300962273.html

    SOURCE Diabetes Research Institute Foundation

    Leave a comment

    Diabetes Treatment: Scientists Find A Healthy Diet To Reduce Insulin Use

    People with diabetes may no longer have to depend on insulin to control their blood sugar levels. Scientists have found a healthy way to reduce the use of this drug in people with high blood sugar levels.

    The researchers from the Hebrew University of Jerusalem found that a three-meal diet with carbohydrate-rich breakfast can reduce insulin use in people with type 2 diabetes. According to the research team, the diet plan is so effective that a significant reduction in insulin use will be visible in three months.

    A three-meal diet, in contrast to an isocaloric six-meal diet, can lead to weight loss, a significant reduction in hemoglobin A1c (HbA1c), appetite and overall glycemia. This will, in turn, decrease the daily insulin use among people with high blood sugar, the researchers said.

    For the study, the researchers observed 28 diabetes patients with obesity or overweight. The participants were then divided into two groups. While the first group was assigned a balanced three-meal diet, the second group was randomly asked to follow a six-meal diet for 12 weeks.

    At the beginning of the study, researchers assessed body weight, glycemic control, appetite, continuous glucose monitoring and clock gene expression of each of the participants. They were assessed again at the second and 12th week of the study.

    During the final analysis, the study team found that a balanced three-meal diet was more effective than a six-meal diet in significant weight loss and decreased HbA1c.  They concluded the research by stating that "upregulation of clock genes seen in this diet intervention could contribute to the improved glucose metabolism."

    The study was conducted in collaboration with the researchers from Wolfson Medical Center in central Israel.

    Nearly 463 million adults are currently living with diabetes globally. Of these, around 80 million people need insulin to control their blood sugar levels, but many of them can't afford it due to its substantial shortages or skyrocketing prices.

    To address this issue, the World Health Organisation (WHO) launched a plan on Wednesday that encouraged pharmaceutical companies to come forward for producing insulin.

    "The simple fact is, that the prevalence of diabetes is growing, the amount of insulin available to treat diabetes is too low, the prices are too high, so we need to do something," Emer Cooke, the WHO's head of regulation of medicines and health technologies, said. "We're confident that competition will bring prices down. That way, countries will have a greater choice of products that are more affordable."

    Insulin ShotThe new insulin pill system will inject from the inside after being swallowed, thus sparing patients from any pain. Pictured: A picture taken on March 14, 2016 shows a solution destiny syringe treatment of severe hypoglycemia that may occur in diabetics using insulin in Paris Photo: Getty Images/Franck Fife/AFP

    Leave a comment

    Fiona Wylde: How This World Champion Athlete Overcomes Type 1 Diabetes

    Fiona Wylde (seen along with professional dancer Christina Martin to her right) participate in a ... [+] panel during the Juvenile Diabetes Research Foundation (JDRF) 2019 Children's Congress on July 09, 2019 in Washington, DC. (Photo by Jemal Countess/Getty Images for JDRF )

    Getty Images for JDRF

    What's SUP?

    SUP stands for stand up paddleboarding and is a sport that, unlike American football, is exactly what its name implies. It consists of you standing up on a board in the water and using a large paddle to propel you forward. It's a growing sport and has different variations, including racing and surfing versions.

    At 22 years young, Fiona Wylde is already a superstar in the sport. From 2016 to 2018, she was the U.S.'s highest-ranked stand up paddle athlete for three years straight. In 2017, Wylde became the Association of Paddle Professional's (APP's) Overall World Champion, having finished second in the world in both racing and surfing that year. And, oh, by the way, she has Type 1 diabetes.

    Yes, Wylde has reached the pinnacle of a sport that includes doing this:

    Fiona Wylde tackles the waves while warming up for this year's Red Bull Heavy Water Event in San ... [+] Francisco, CA. (Photo: Courtesy of Fiona Wylde)

    Courtesy of Fiona Wylde

    Athlete meet big wave. For most of us, our board, paddle, body, and dignity would have been separated from each other by the wave long before this picture could have been taken. But that's not the case with Wylde.

    The picture above was from one of Wylde's warm-up runs for the Red Bull Heavy Water event in San Francisco, CA, last month. The event, which is one of the stops on the 2019 APP World Tour circuit, involved a 12 kilometer or 7.5 mile course through the very choppy San Francisco Bay waters under the Golden Gate Bridge and to Ocean Beach, where waves hit the shore. Here is how the "under the Golden Gate Bridge" part of the race looked like:

    Here is the approach the Golden Gate Bridge during the Red Bull Heavy Water competition in San ... [+] Francisco in October. (Photo: Brian Bielmann/Red Bull Content Pool)

    BRIAN BIELMANN/RED BULL CONTENT POOL

    Next, after the Golden Gate Bridge, the course took the competitors through even choppier waves:

    (Photo: Brian Bielmann/Red Bull Content Pool)

    Brian Bielmann/Red Bull Content Pool

    Then, there's this part, for which the word "choppy" can no longer apply:

    Here a participant, not Wylde, battles a wave near Ocean Beach in the Red Bull Heavy Water event. ... [+] (Photo: Brian Bielmann/Red Bull Content Pool)

    Brian Bielmann/Red Bull Content Pool

    No, these waves have gone beyond chopping, having progressed to perhaps slicing or maybe blendering or even turn-you-upside-downing. As you can see, this event combined different aspects of racing and surfing, making it what Wylde called "one of the most challenging events around."

    Not all events have both the racing and surfing parts. In fact, many focus on one or the other. As Wylde described, "in racing, you can be in an extended full out sprint across an ocean, lake, or river. Stand up paddle surfing is more like traditional surfing but with a paddle." Both stand up paddle racing and surfing at their highest levels require world class endurance, balance, and strength. To excel at one is enough of an achievement. To excel at both racing and surfing is very Wylde, so to speak.

    What's even more Wylde is the fact that she's had to also overcome Type 1 diabetes, which is a very tough competitor that's typically there for life, as there is no cure. Just as racing and surfing are quite different, so are Type 1 and Type 2 diabetes. In Type 1 diabetes, which used to be called more often juvenile diabetes or insulin-dependent diabetes, your pancreas cannot produce enough insulin, the hormone that helps sugar get from your bloodstream into your cells. Your cells need sugar to survive and function. Thus, no insulin, no life.

    Normally, cells in your pancreas called beta islet cells produce insulin. However, Type 1 diabetes is an auto-immune disease, meaning that your immune system gets a bit confused and attacks and destroys your own beta islet cells. Your beta islet cells may fight the good fight for a while to continue producing insulin but eventually in Type 1 diabetes, they succumb. This is very different from Type 2 diabetes in which your pancreas may produce enough insulin but the cells in your body don't respond as well to the hormone.

    Depending on when the autoimmune process may have started and how resilient your beta islet cells may be, it can take while to notice the symptoms of Type 1 diabetes. Wylde didn't notice anything was amiss until her senior year in high school. She was already a top stand up paddle racer and surfer, taking the last three years of high school online to allow her to travel around the world for competitions.

    "All went well for the first four months," Wylde explained. "But during a 12.5 mile race, I went from second to sixth. I also noticed that I was losing a bunch of weight, but thought it was because I was training harder."

    As is often the case with chronic conditions, Wylde went a while before a clear diagnosis emerged. "I took three different trips to the doctor," she recalled. "The day I graduated from high school, I went to doctor's office and came back with a Type 1 diabetes diagnosis." Not exactly the best graduation present.

    When you get such a life-altering diagnosis, it can be easy to want to give up rather than continue to SUP competitively as Wylde had since age 10. However, as Wylde relayed, "I didn't let it stop me. I kept going and flew to Europe to go race. My dad came with me to help me." The next year she won the world title. So much for Type 1 diabetes getting in the way with what she wanted to do.

    This video from her YouTube channel shows her in action, doing what she has wanted to do:

    This doesn't mean that type 1 diabetes hasn't changed her life. She wears a Dexcom device to continuously monitor her blood sugar (glucose) levels. This helps her determine when to use an InPen insulin injector pen to give herself the appropriate amount of insulin. The pen has an accompanying app on her smartphone that can help track her injections.

    Controlling ones blood sugar in such a manner can be challenging even in the relatively controlled setting of a 9-to-5 office job, assuming that the office isn't regularly flooded with water and you don't move to and from the water cooler on a board with a paddle. Competing as Wylde does throws in a lot more variables. As she indicated, "adrenaline raises blood sugar." She also travels quite a lot for competitions, which makes it more difficult to keep track of everything, including what she eats.

    Then, there's the mental adjustment that she's had to make. "It has been a big mental adjustment," she said. "It's made me appreciate the value of having a healthy working body. As a result, I have done a better job of taking care of yourself. For example, I have learned what to eat before races."

    She added that Type 1 diabetes has "made me much more aware of everything that needs to be done and prepare more for things. When I travel, I need to make sure that I have all the devices and medical supplies and the food. I realized that I can't just wing it anymore. I can't take that risk."

    Here Fiona Wylde walks up shore with her equipment during a preparation in San Francisco. (Photo: ... [+] Sean Greeley)

    Sean Greeley

    Her life got even more complicated a year later when she was diagnosed with celiac disease. This meant that she has to be even more careful about what she eats and avoid foods containing gluten. But as with her diabetes diagnosis, she has taken this additional diagnosis in stride, or rather in paddle.

    Of course, athletics has also helped Wylde deal with her diagnoses. After all, as she related, "exercise is the billion dollar drug. Being active and healthy makes feel so much better. When I have exercised, the amount of insulin I have needed is reduced."

    There are also the mental health benefits. "It clears my mind," she said. "When I am out there on the water, I am paying attention to the water. The water is never still. You have to pay attention to the conditions and the people around you. You have to find the biggest current line and the biggest eddy."

    Additionally, sports can provide a community, which certainly helps deal with different challenges. "The stand up paddleboarding community is so positive and fun to hang out with. It's where I have made my best friends."

    Thus, if you ask Wylde what's up, the answer is SUP and a lot. She just finished second among the women at the Red Bull Heavy Water event. She is currently sitting number two in stand up surfing and "would like to win a stand up surfing world title." Oh, and she is also going to Oregon State University where she is studying geography and geospatial sciences. This is fitting since she has already managed to navigate her way through the challenges of both Type 1 diabetes and being a world champion "water woman."

    Leave a comment

    There Are 4 Ways to Manage Your Type 1 Diabetes Through Treatment—Here's How

    Only about 5% of those diagnosed with diabetes have type 1, which is why it may seem like this version of the disease seems a little more mysterious than type 2 diabetes—and with good reason: No one knows quite how to prevent type 1 diabetes yet, according to the Centers for Disease Control and Prevention (CDC).

    That said, there are ways to type 1 diabetes, including living a healthy lifestyle and getting regular health checkups. Another important factor in type 1 diabetes management? Following a strict treatment plan, according to experts. Here's what you need to know about diabetes treatment options, if you or a loved one has been diagnosed with the condition.

    What is type 1 diabetes, again?

    When you have type 1 diabetes, your pancreas doesn't make much or any insulin, a hormone that that allows blood sugar to enter the cells in your body where it's used for energy, the CDC explains.

    When you don't have insulin, blood sugar can't get into your cells and builds up in the bloodstream. That causes high blood sugar, which is bad for your body. High blood sugar causes many of the symptoms and complications of diabetes, like peeing a lot, feeling very thirsty, losing weight without trying, feeling very hungry, having blurry vision, having numbness or tingling, and feeling very tired, the CDC says.

    Symptoms of type 1 diabetes can develop over a few weeks or months. And, while it usually starts when someone is a child or young adult, it can technically come on at any age.

    RELATED: 6 Facts People With Type 1 Diabetes Want You to Know

    So, how is type 1 diabetes treated?

    Type 1 diabetes is detected through a simple blood test. If you have the disease, your doctor will likely give you some options when it comes to treatment—and a lot of it is managed by you.

    1. Take regular insulin shots or a use an insulin pump

    People with type 1 diabetes will need to take regular insulin shots or wear an insulin pump that delivers insulin directly into their body. This insulin helps manage blood sugar levels, Kathleen Dungan, M.D., an endocrinologist at The Ohio State University Wexner Medical Center, tells Health. Unfortunately, insulin can't be taken as a pill because the acid in your stomach destroys it before it can reach your bloodstre am, the CDC explains.

    As for whether shots or a pump is best, it depends. "Therapies are usually individualized to patients," Katherine Araque, M.D., director of endocrinology of the Pacific Neuroscience Institute at Providence Saint John's Health Center in Santa Monica, California, tells Health. For people who prefer to do insulin shots, they'll generally need to take a long-acting insulin and then do insulin injections before mea ls and bedtime, she says.

    That's a lot of injections, which is why doctors generally recommend using a pump. "We usually like to have patients on insulin pumps if they can safely manage them because they're easier and more flexible for people with diabetes," Dr. Dungan says. Some newer pumps can "provide more of an automated insulin delivery, so a patient is not constantly having to make adjustments," she says.

    RELATED: The 7 Most Common Diabetes-Related Medical Emergencies

    2. Check blood sugar regularly

    Specifics on this tend to vary by patient. "Typically, people with type 1 diabetes need to check their blood sugar at least four times a day, but we have good data that show that the more they check, the better their overall control is," says Dr. Dungan.

    Everyone's target blood sugar levels are slightly different, but the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) says that targets usually are between 80 and 130 before you have a meal and below 180 two hours after the start of the meal.

    Traditionally blood sugar has been checked with a finger stick blood glucose test, but there are continuous glucose monitors available that measure the glucose levels under your skin every five minutes. "We prefer that most patients be on a continuous glucose monitor to minimize the number of finger sticks they have to do," says Dr. Dungan.

    3. Have strategies in place for when blood sugar levels are off

    High blood sugar (aka hyperglycemia) happens when your blood sugar level is higher than your target or 180. This can cause symptoms like feeling really tired, having blurry vision, or needing to pee more often than usual, the NIDDK says. If this happens, it's best to check your blood sugar and, if it's high, the NIDDK says it's best to drink a large glass of water and go for a "brisk" walk.

    Low blood sugar (aka hypoglycemia) can also be an issue. This is when your blood sugar drops below 70. Symptoms include feeling shaky, sweaty, or very hungry, the NIDDK says. If you have these symptoms and your blood sugar is low, the NIDDK recommends chewing four glucose tablets, drinking four ounces of fruit juice, drinking four ounces of regular (not diet) soda, or chewing four pieces of hard candy right away. Then, wait 15 minutes and check your blood sugar again. Keep doing this until your blood sugar is 70 or above.

    4. Try to manage stress

    It's important for everyone to try to get their stress levels under control, but it's especially crucial for those with type 1 diabetes since stress can make it hard to control blood sugar levels, Dr. Dungan says.

    That's why doctors usually try to advocate for patients to "follow a healthy lifestyle, including eating a balanced diet and getting regular physical activity," Dr. Araque says. "With type 1 diabetes, there are innumerable factors that can affect glucose control," Dr. Dungan says. "Many patients learn patterns of activity, diet, sleep, and stress levels that impact this and figure out how to manage them."

    Managing type 1 diabetes can be "tough," Dr. Dungan admits. But with the right treatment, it's possible to lead a long and healthy life with the disease.

    To get our top stories delivered to your inbox, sign up for the Healthy Living newsletter

    Leave a comment
    Powered by Blogger.

    Search

    Swedish Greys - a WordPress theme from Nordic Themepark. Converted by LiteThemes.com.